SYNB
Putnam BioRevolution ETF
SYNB actively invests in companies of all sizes around the globe that enable biological innovation.
Global
EQUITY
Rules-Based
MANAGEMENT STYLE
4.9 M
ASSETS UNDER MGMT
70 bp
EXPENSES
Fund Basics
| Fund sponsor | Power Corporation of Canada |
| Category | Global |
| Asset class | Equity |
| Website | link... |
| Inception date | Sep 29, 2022 |
| Assets (mns) | $5 |
| Expense ratio | 70 bp |
| Currency | USD |
Sector Breakdown
Fund Structure
| Regulation | Open-Ended Fund |
| Distributions | Annually |
| Taxation | 1099 |
| Stock selection | Proprietary |
| Weighting | Proprietary |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
| THERMO FISHER SCIENTIFIC INC | 6.7 % |
| DANAHER CORP | 5.6 % |
| ABBVIE INC | 5.5 % |
| CORTEVA INC | 4.9 % |
| NOVOZYMES A/S-UNSPONS ADR | 4.6 % |
| BIO-RAD LABORATORIES-CL A | 4.6 % |
| ASTRAZENECA PLC-SPONS ADR | 4.2 % |
| ELI LILLY & CO | 4.0 % |
| ASCENDIS PHARMA A/S | 4.0 % |
| ALPHABET INC. CLASS A | 3.9 % |
Constituent Breakdown
| Number of holdings | 35 |
| Herfindahl-Hirschman Index | 333 |
| Wgt avg mkt cap (mns) | $263,404 |
| Large cap (>$10bn) | 65.5% |
| Mid cap ($2-10bn) | 18.9% |
| Small cap (<$2bn) | 4.6% |
| Developed mkts. | 90.0% |
| Emerging mkts. | 0.0% |
Country Exposure
 |
UNITED STATES | 69.7 % |
 |
DENMARK | 8.6 % |
 |
BRITAIN | 4.2 % |
 |
SWITZERLAND | 2.2 % |
 |
GERMANY | 2.0 % |
 |
NORWAY | 1.6 % |
 |
NETHERLANDS | 1.5 % |
Historical Performance
Standardized Performance (as of 04/30/2025)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -6.3% | -5.7% | 0.5% | -- | -- | -- | -- | 4.4% |
| Dividend Yield | 0.0% | 0.0% | 0.0% | -- | -- | -- | -- | 0.0% |
| Total Returns | -6.3% | -5.7% | 0.6% | -- | -- | -- | -- | 4.4% |
| Ann. Volatility | 25.0% | 18.4% | 16.3% | -- | -- | -- | -- | 17.3% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.05 | 79% |
| MSCI EAFE | 0.95 | 69% |
| MSCI Emg Mkts | 0.88 | 54% |
Liquidity Measures
| Avg. volume (000) | 0 |
| ADV traded (mns) | $0 |
| Turnover | 0.0% |
| Avg. Bid/Ask (% of price) | 0.34% |
Technical Indicators
| Recent close | $27.82 |
| 30d moving avg. | $26.81 |
| Annualized volatility | 15.9% |
| Relative strength (RSI) | 45 |
| Short interest | 0.0% |
Distributions
Assets Under Management (mns)
Money Flows (mns)
Short Interest (as % of shares outstanding)
Long Money Flows (mns)
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. |
Expenses vs. |
ALTAR Score™ vs. |
|---|---|---|---|---|
| HELX | Franklin Genomic Advancements ETF | 28.4% | -20 bp | -0.2% |
| WDNA | WisdomTree BioRevolution Fund | 22.2% | -25 bp | -1.7% |
| PINK | Simplify Health Care ETF | 21.4% | -20 bp | +1.0% |
| IYH | iShares U.S. Healthcare ETF | 20.7% | -30 bp | +6.9% |
| FHLC | Fidelity MSCI Health Care Index ETF | 20.4% | -62 bp | +6.3% |
| XLV | Health Care Select Sector SPDR Fund | 19.5% | -62 bp | +7.6% |
| VHT | Vanguard Health Care ETF | 19.5% | -60 bp | +6.1% |
| MEDX | Horizon Kinetics Medical ETF | 17.7% | +15 bp | +2.1% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 17.2% | -10 bp | +11.3% |
| HRTS | Tema GLP-1 Obesity & Cardiometabolic ETF | 17.1% | +5 bp | +1.0% |
Risk and Returns: vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- | |
| Book value per share | -- | -- | -- | -- | -- | -- | -- | |
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2024 | 2025 | 2026 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 5/13/2025
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
UNDERWEIGHT
Below average appreciation potential. A rating of UNDERWEIGHT is assigned to ETFs with ALTAR Scores in the 2nd quintile (ranking higher than only 20%-40%) of their category. Typically, funds in this category consist of stocks trading at relatively expensive valuations and/or having below-average fundamentals.
ALTAR Score™
2.9%
Cat. Avg
4.6%
ALTAR Score™ Calculation
Category Overview
There are 365 funds in the Global Equity category, with an average ALTAR Score™
of 4.6% and a standard deviation of
3.5%. 's ALTAR Score™ is approximately
0.5 standard deviations
below
the category average. This places in the 31st percentile among funds in the category.
Sell Side Consensus Rating
Sell-side recommendations on the ETF's individual constituents
SYNBSELL
U/W
HOLD
O/W
BUY
Expense Analysis
| Peer Group | Rules-Based Global Equity ETFs |
| # of ETFs | 191 |
| Avg. Expense Ratio | 55.4 bp |
| Std. Deviation | 17.5 bp |
| (70 bp) Percentile rank | 80 |
Peer Group Expense Ratio Distribution
Total Cost of Ownership (TCO) Comparison
| Expense (bp) (A) |
Avg. Bid/Ask (bp) (B) |
TCO (bp) (A)+(B) |
|
|---|---|---|---|
| 70.0 | 0.0 | 70 | |
| Peer Avg. | 72.7 | 38.8 | 111.5 |
For a detailed cost analysis of this and any other ETF use the TCO Comparison Tool .